



FAES FARMA, S.A. submits the following Relevant Communication to the Spanish Securities Market National Commission (CNMV):

#### RELEVANT COMMUNICATION

##### FAES FARMA signs a transcendental agreement for bilastine in Japan

Today Faes Farma S.A. and Taiho Pharmaceutical CO., LTD. have signed in Japan a license agreement for the development and marketing of bilastine in the Japanese market.

As a result of this agreement, Taiho will obtain a license to develop and market bilastine in Japan and Faes Farma will receive an initial payment of ten million euros (€ 10.000.000) plus milestone payments for bilastine development and marketing achievements, as well as double-digit royalties on bilastine sales achieved by Taiho, after its marketing authorization.

All development and marketing costs of Bilastine in Japan will be covered by Taiho.

Following is the press release that will be sent to the media today in relation to this subject matter.

Tokushima (Japan), July 24<sup>th</sup> 2012



## FORM OF PRESS RELEASES

(i) Spanish Announcement

### **FAES FARMA licenses bilastine to Taiho for Japanese Market**

- **Faes Farma and Taiho Pharmaceutical have entered into a license agreement to develop and commercialize Faes' anti-allergy product, bilastine, in Japan.**
- **Faes Farma will receive initial payment at the signature of € 10 m. plus milestone payments and double-digit royalties on sales of bilastine in Japan.**
- **Japan accounts for roughly one third of worldwide allergy sales**
- **bilastine is an innovative anti-histamine product fully developed by Faes Farma.**

**Madrid, July 24th, 2012.**

Faes Farma S.A. and Taiho Pharmaceutical CO., LTD., today announced a license agreement covering the development and commercialization of Faes's anti-allergy product, bilastine, for the Japanese market.

Bilastine is an innovative anti-allergy product fully developed by Faes Farma.

In October 2010, it received marketing authorisation from the European Authorities for the treatment of allergic rhinoconjunctivitis and urticaria.

With this agreement, Taiho obtains a license to develop and commercialize bilastine in Japan, and Faes Farma receives an initial payment at the signature of € 10 m. plus milestones payments and double-digit royalties on sales. All development and marketing costs of bilastine in Japan will be covered by Taiho.



Mr. Eduardo Fernández de Valderrama, Chairman and CEO of FAES FARMA, stated: “This agreement, comes as a long awaited reward to the research and financial efforts deployed with bilastine. Japan accounts for roughly one third of the world’s sales of allergy products, and we are convinced that with Taiho we found the best partner for this market. Considered with the rest of licenses of bilastine signed altogether, they will allow Faes Farma to walk a path of strong growth in results, growth that will be sustained for the mid and long term.

Mr. Masayuki Kobayashi, President of Taiho Pharmaceutical, said “We are very pleased to establish a partnership with Faes Farma, the leading Spanish pharmaceutical laboratories of innovative medicine. Allergy is one of the focused areas for Taiho Pharmaceutical and we believe that bilastine will contribute to the treatment of Japanese patients for allergic rhinoconjunctivitis and urticaria”

#### **About bilastine**

Bilastine, is an innovative anti-histamine product, fully developed by Faes for the treatment of symptoms of allergic rhinoconjunctivitis and urticaria.

Bilastine has obtained a market share of 16 % in Spanish market, after the first year, and has been successfully launched in other countries such as France, Brazil, etc.

The product has been licensed to important companies such as Pfizer, GSK, Takeda, Menarini, Merck Serono, Invida, Pierre Fabre, Yuhan, Hikma or Kalbe, leaders in different markets.

Bilastine has a unique safety profile, with the same efficacy as the best existing alternatives.

#### **Faes Farma**

Faes Farma, is one of the leading Spanish pharmaceutical laboratories, focused on research, manufacture and commercialization of innovative medicines.

With strong presence also in Portugal, Latin America and Africa, Faes Farma is now developing an intense process of internationalization. Bilastine shall be a key element in this process. For more information about Faes, please visit the company's Web site at [www.faes.es](http://www.faes.es)



### **Taiho Pharmaceutical**

Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd., (<http://www.otsuka.com/en/>) is an R&D-driven specialty pharma focusing on the three fields of allergies/immunology, oncology, and urology. Its corporate philosophy takes the form of a pledge: “We strive to improve human health and contribute to the society enriched by smiles.” Taiho Pharmaceutical creates quality products that effectively treat medical conditions and can help improve people’s quality of life.

For more information about Taiho Pharmaceutical, please visit <http://www.taiho.co.jp/english/>